Active Clinical Trials
The division's clinical research team supports the clinical studies across the division's three departments: Anesthesiology & Perioperative Medicine, Critical Care and Pain Medicine. The team consists of study coordinators, research assistants and data managers. This is an experienced team of clinical researchers ready to support studies of all phases. If you are interested in participating in any of these studies, please contact Chris Rubio, Director of Research Development, at 713-745-5824, or e-mail at email@example.com.
Active or Upcoming Studies Include:
Psychophysical Studies of Cancer Therapy-Induced Pain
The aim of this study is to examine the feasibility of using quantitative sensory testing procedures, widely applied to the experimental study of sensory processing in humans both with and without various pain syndromes, to now characterize the psychophysical properties of neuropathic pain that has developed as a consequence of cancer therapy. Skin punch biopsies will be performed in patients with chemotherapy-induced pain to determine whether the impairment of nerve function is due to actual retraction or loss of innervation to the skin in areas affected by sensory disturbance.
Observational Study of Functional Hemodynamics During One Lung Ventilation
This is an observational study that will investigate the changes from baseline in functional hemodynamic variables as measured by an arterial pressure cardiac output device during the intraoperative and postoperiative period when respiratory maneuvers are preformed during and after elective thoracic surgeries.
Currently Phase III clinical trials are planned for OIC in non-cancer patients. Patients with cancer pain constitute another viable target population to test the effects of NKTR-118. Because cancer pain patients tend to be on higher opioid doses and have different comorbidities than non-cancer pain patients, demonstrating efficacy and safety for NKTR-118 in this high medical need subpopulation would be useful. Thus, the goal of this Phase III study is to demonstrate that NKTR-118 is efficacious, generally safe and well tolerated in the treatment of OIC in cancer patients taking opioids for pain related to malignancy.